pull down to refresh

I think this is setting the stage for there to be restrictions on the (much cheaper) compounding of semaglutide.
A quote:
Lilly said in an open letter that it was “deeply concerned” about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.
Note how they're connecting "compounding" with "phony".